Non-ergot dopamine agonist with preferential affinity for the D3 receptor (within the D2 receptor family); first-line for Parkinson's disease and restless legs syndrome.
Half-Life & Elimination Curve (PO: 8h)
Plasma (PO)t½ Decay (8h)Effect Site (ke0)
0×t½0h100%(0.756 µg/L)
1×t½8h50%(0.378 µg/L)
2×t½16h25%(0.189 µg/L)
3×t½24h12.5%(0.0945 µg/L)
4×t½32h6.3%(0.0472 µg/L)
5×t½40h3.1%(0.0236 µg/L)
Elimination t½8h (PO)
Rate Constant (ke)0.0866 h⁻¹
Time to Peak (Tmax)2.02h
Est. Peak (Cmax)0.756 µg/L
Clearance (CL)43.3 L/h
97% Washout (5×t½)40h
Dosing Guidelines
Oral (PO): Typical 0.5 mg (Range: 0.125–1.5 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 90% · Volume of Distribution (Vd): 500 L · Absorption (ka): 1.5 h⁻¹ (t½ka ≈ 28m)
PK from FDA prescribing information (DailyMed setid 46f88017-7b0e-437e-90b1-37bdf9013e72): absolute bioavailability >90% (F 0.9), apparent Vd ~500 L, terminal t½ ~8 h (young)/~12 h (elderly), Tmax ~2 h, ~90% excreted unchanged in urine. ka_hr 1.5 derived from Tmax 2 h (ke from t½ 8 h). Human D2 affinity not authored — GtoPdb's curated human range (pKi 5.1–7.4) is too wide to pin a value.